Policy
In a Cabinet meeting, Health Secretary Robert F. Kennedy Jr. said the website could go live “probably in the next 10 days,” but an exact launch date remains unclear.
FEATURED STORIES
An inconsistent boom-and-bust cycle funding environment for early-stage biotech innovations and burdensome regulation threaten the U.S.’s half-century-long dominance in the biotech sector.
Acadia Pharma’s Catherine Owen Adams is one of the founders of a group of small- to mid-cap biotechs advocating against a ‘peanut butter blanket’ approach to drug pricing for small companies.
Former European Trade Commissioner Phil Hogan and former U.S. Senator Richard Burr, speaking on a panel at the J.P. Morgan Healthcare Conference, pushed to see a larger picture beyond the Trump administration’s year of chaos and confusion.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
Harris fired the first shots on Monday.
Baker and ex-ArthroCare CFO Michael Gluk were convicted in June 2014 on charges that they ran a scheme to generate false revenue numbers
Shares of TherapeuticsMD have shot up more than 51 percent in morning trading after the FDA reversed course on its rejection of that company’s vaginal pain medication.
Osiris has settled a case of accounting fraud with the U.S. SEC, but four former company execs will face charges for the alleged financial misreporting.
Despite Brandicourt’s positive spin, investors were displeased as the company’s financial report fell shy of analysts’ expectations.
Mylan’s second-ranked exec allegedly took an active role in a vast and “sinister” price-fixing conspiracy among global makers of generic pills.
The FDA’s Psychopharmacologic Drugs Advisory Committee and Drug Safety and Risk Management Advisory Committee voted 18 to 1 to recommend Indivior’s RBP-6000 to treat opioid use disorder.
Here’s a closer look at six drugs facing FDA decisions in November.
Insys continues to receive an optics beating in the wake of the charges against company founder John Kapoor and multiple executives surrounding illegal sales practices of its cancer pain drug.
Suzhou’s MabSpace Biosciences filed an IND application with the CFDA last month to begin human testing of a second-generation PD-L1 antibody.